NVCR - NovoCure Limited

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
35.500
+0.050 (+0.14%)
As of 2:46PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close35.450
Open35.500
Bid35.450 x 900
Ask35.500 x 1300
Day's Range35.145 - 35.850
52 Week Range16.100 - 38.650
Volume146,186
Avg. Volume718,293
Market Cap3.284B
Beta3.14
PE Ratio (TTM)N/A
EPS (TTM)-0.721
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.40
Trade prices are not sourced from all markets
  • What Does NovoCure’s Valuation Trend Indicate?
    Market Realist3 days ago

    What Does NovoCure’s Valuation Trend Indicate?

    NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.

  • NovoCure Stock: Key Factors Driving Investors’ Interest
    Market Realist3 days ago

    NovoCure Stock: Key Factors Driving Investors’ Interest

    NovoCure (NVCR) is mainly engaged in developing and bringing tumor treating fields for solid tumors to the market. The company’s first tumor treating fields delivery system, Optune, is targeted to treat adult patients with glioblastoma. Tumor treating fields use electric fields tuned to certain frequencies to disrupt solid tumor cancer cell division.

  • NovoCure’s Top Line Registered Strong Growth
    Market Realist3 days ago

    NovoCure’s Top Line Registered Strong Growth

    NovoCure (NVCR) generated revenues of $61.51 million in the second quarter—compared to $38.38 million in the second quarter of 2017. The growth was also driven by NovoCure’s initial launch efforts in Japan. NovoCure incurred a cost of revenues of $19.83 million in the second quarter—compared to $13.15 million in the second quarter of 2017.

  • ACCESSWIRE3 days ago

    This $7 Biotech Stock Could Be Worth $20 or More After Recent Developments

    Orgenesis (ORGS) is an underfollowed player in the biotech sector, but with growing revenue and high-profile clients and partners. Most recently, a prestigious healthcare institute Great Point Partners invested up to $25 million directly in their subsidiary and is acting as a key advisor for their global business expansion. Fundamentals are looking good at ORGS as revenue climbed 73% in fiscal Q2, over the year-ago period.

  • Benzinga5 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Canopy Growth Corp (NYSE: CGC ) stock gained more ...

  • Business Wire5 days ago

    Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

    Novocure (NVCR) and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.

  • Forget Bitcoin: You're Better Off Buying These 3 Stocks
    Motley Fool14 days ago

    Forget Bitcoin: You're Better Off Buying These 3 Stocks

    Cryptocurrencies might grab all of the headlines, but these three businesses are better bets for the long term.

  • Business Wire17 days ago

    Novocure to Present at Two Upcoming Investor Conferences

    Novocure announced today that it will participate in two upcoming investor conferences.

  • Business Wire18 days ago

    Novocure Announces Addition to Its Board of Directors

    Novocure (NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018. “We are extremely pleased to welcome Jeri to our board of directors,” said Bill Doyle, Novocure’s Executive Chairman.

  • Business Wire20 days ago

    Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer

    Novocure (NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology. The INNOVATE trial was a prospective, single-arm study testing the feasibility, safety and preliminary efficacy of Tumor Treating Fields combined with weekly paclitaxel in recurrent ovarian cancer. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.

  • NovoCure’s Revenues Rose 60% in the Second Quarter
    Market Realist24 days ago

    NovoCure’s Revenues Rose 60% in the Second Quarter

    NovoCure (NVCR) released its second-quarter results on July 26. In the second quarter, NovoCure continued to see steady growth in patient prescriptions for new glioblastoma diagnosis. NovoCure reported a net loss of $15.51 million in the second quarter—compared to a net loss of $21.17 million in the second quarter of 2017.

  • Thomson Reuters StreetEvents25 days ago

    Edited Transcript of NVCR earnings conference call or presentation 26-Jul-18 12:00pm GMT

    Q2 2018 Novocure Ltd Earnings Call

  • Business Wire25 days ago

    Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update

    Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018

  • What to Expect from NovoCure’s Q2 2018 Earnings
    Market Realist26 days ago

    What to Expect from NovoCure’s Q2 2018 Earnings

    NovoCure (NVCR) is expected to report its second-quarter earnings on July 26. In this series, we’ll look at the company’s top-line, operational, and bottom-line performance expected by analysts for the second quarter. We’ll also look at analysts’ recommendations and the performance of NovoCure stock so far this year.

  • Why Most Analysts Are Bullish on NovoCure
    Market Realist26 days ago

    Why Most Analysts Are Bullish on NovoCure

    NovoCure (NVCR) is expected to incur SG&A (selling, general, and administrative) expenses of $35.4 million in the second quarter, compared with $31.38 million in the second quarter of 2017, an increase of 12.8%. NovoCure’s R&D (research and development) expenses are expected to increase 47.06% from $9.37 million in the second quarter of 2017 to $13.78 million in the second quarter. NovoCure’s total operating expenses are expected to increase 18.1% from $40.75 million in the second quarter of 2017 to $48.13 million in the second quarter.

  • Business Wirelast month

    Novocure Announces 13 Presentations at American Society for Radiation Oncology 2018 Annual Meeting

    The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference

  • Market Realistlast month

    NASDAQ All-Stars

    Batting first and playing RF, we have GDS Holdings Ltd. (NASDAQ: GDS). GDS is one of the leading carrier-neutral data center solutions providers in China, and the growing demand for its services has led to impressive growth.

  • NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%
    Zackslast month

    NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%

    NovoCure (NVCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Business Wirelast month

    Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society

    The IEEE Engineering in Medicine and Biology Society’s 40th International Conference is the first conference in which a scientific track will be devoted to Tumor Treating Fields, i

  • ACCESSWIRElast month

    Free Pre-Market Technical Recap on Nevro and Three Additional Medical Equipment Stocks

    On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: Nevro Corp. (NYSE: NVRO), NovoCure Ltd (NASDAQ: NVCR), NuVasive Inc. (NASDAQ: NUVA), and Stryker Corp. (NYSE: SYK).

  • Here's Why Novocure Ltd. Rose 55% in the First Half of 2018
    Motley Foollast month

    Here's Why Novocure Ltd. Rose 55% in the First Half of 2018

    Fighting cancer with electric fields could be a huge business.

  • InvestorPlacelast month

    Trade of the Day: Novocure Ltd (NVCR)

    To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.

  • Business Wire2 months ago

    Novocure Appoints Pritesh Shah as Chief Commercial Officer

    Novocure (NVCR) announced today that Pritesh Shah has been appointed as Novocure’s Chief Commercial Officer, reporting to Novocure’s Chief Executive Officer Asaf Danziger. In this role, Mr. Shah will be responsible for the development and execution of Novocure’s commercialization strategy worldwide, and for overseeing Novocure’s international business units.

  • Business Wire2 months ago

    Novocure to Report Second Quarter 2018 Financial Results

    Novocure announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2018, at 8 a.m.

  • TheStreet.com2 months ago

    NovoCure's Charts Look Bullish

    NovoCure Limited made a small base pattern in 2016 and started a strong rally in 2017 and moving up four-fold from its 2017 nadir. Let's review the charts and indicators of NVCR to see what the prospects look like for this company.